相关实验视频

Updated: Sep 15, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

乙甲基胆酶 (BChE) 降低对高素抗性的调节:对前列腺癌的影响

Buse Cevatemre^1,2, Arda Işiklar³, İpek Bulut²

¹Division of Medical Biology, Faculty of Medicine, Koç University, İstanbul, Turkiye.

Turkish journal of biology = Turk biyoloji dergisi

|July 18, 2025

概括

乙基胆酶 (BChE) 的降低调节使得割耐性前列腺癌 (CRPC) 中的税抗性产生. 较低的BChE水平与化疗耐药性有关,并可能作为前列腺癌进展的生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

化疗耐药性,特别是对像多塞塔克塞尔和卡巴西塔克塞尔这样的税类药物,是治疗抗割前列腺癌 (CRPC) 的重大挑战.
目前尚不完全了解CRPC中抗分的分子机制,因此需要确定新的治疗点和生物标志物.
虽然在各种癌症中已经观察到降低的丁胆酶 (BChE),但其在化疗耐药性方面的具体作用仍然在很大程度上未被探索.

研究的目的:

调查丁胆酶 (BChE) 在割耐性前列腺癌 (CRPC) 中对税耐药性发展中的作用.
为了确定BCHE表达水平是否与CRPC细胞模型中的税种敏感性或耐药性相关.
探索BChE作为前列腺癌进展的生物标志物的潜力.

主要方法:

转录组分析 (RNA测序) 用于识别分类抗和敏感CRPC细胞之间的差异表达基因.
在CRPC细胞系中验证BChE表达.
使用lentiviral过度表达和shRNA/gRNA (CRISPR-Cas9) 介导的枯竭来操纵BCHE水平.
在使用公开数据库和癌症基因组图谱 (TCGA) 的患者样本中分析BChEmRNA水平.

主要成果:

与父细胞相比,丁胆酶 (BChE) 被确定为与税抗性CRPC细胞中最显著下调的基因.
在父母CRPC细胞中抑制BChE导致对税获得的耐药性.
抗性细胞中BChE的过度表达并没有恢复对税的敏感性.
在包括前列腺癌在内的各种癌症患者样本中观察到降低的BCHEmRNA水平.
通过TCGA分析,BCHE被确定为前列腺癌中治疗后显著的瘤标志物.

结论:

丁胆酶 (BChE) 的降低调节在割耐性前列腺癌 (CRPC) 中赋予高素抗性方面发挥着至关重要的作用.
抑制BChE足以在敏感的CRPC细胞中诱导税抗性.
BChE可以作为一种潜在的生物标志物,用于跟踪前列腺癌的疾病进展,特别是在治疗后.

关键词:

前列腺癌是什么意思前列腺癌是什么意思化疗化疗是一种化学疗法.药物耐药性耐药性药物耐药性纳税人就是纳税人.

更多相关视频

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...